The U.S. Food and Drug Administration has approved Crinetics Pharmaceuticals’ Palsonify (paltusotine), marking the company's first authorized product. This once-daily oral therapy targets acromegaly patients who are ineligible for surgery or have insufficient response to it. Clinical trials demonstrated significant reductions in growth hormone levels and a favorable safety profile. This approval positions Crinetics to compete with established injectable acromegaly drugs from Novartis and Ipsen.